乙型肝炎的功能疗法:当前和未来的前景
Sudheer Marrapu1, Jinit R Soni1, Kislaya Kamal1
1Department of Gastroenterology, All India Institute of Medical Sciences, Patna 801507, India.
实现慢性乙型肝炎 (CHB) 的功能治愈需要乙型肝炎表面抗原 (HBsAg) 的损失. 目前的治疗方法表现出有限的成功,需要新的疗法来克服CHB发病障碍.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
背景情况:
- 慢性乙型肝炎 (CHB) 影响全球超过2.5亿人.
- 功能性治疗,标志着HBsAg损失和无法检测到的HBVDNA,是治疗的主要目标.
- 包括病毒DNA整合和免疫功能障碍在内的CHB病变,阻碍HBsAg清除.
研究的目的:
- 审查当前对HBsAg血清清除在CHB中的理解.
- 讨论CHB的临床意义和实现功能治疗的挑战.
- 探索CHB不断变化的治疗环境.
主要方法:
- 关于CHB病原和治疗的当前文献的综述.
- 对HBsAg血清清除现有治疗结果的分析.
- 讨论新型治疗策略及其潜力.
主要成果:
- 目前的治疗方法 (NAs,基化干扰素) 产生较低的HBsAg血清清除率 (3-14%).
- 对HBsAg清除的重大障碍包括病毒持久性和免疫力受损.
- 新型抗病毒药物和免疫疗法正在研究中.
结论:
- 由于复杂的病毒和宿主因素,实现CHB的功能治疗仍然具有挑战性.
- 针对HBV生命周期和免疫反应的新疗法至关重要.
- 仔细选择患者进行NA终止可能有助于HBsAg损失,但需要谨慎监测.
更多相关视频
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
相关概念视频
Microorganisms in Medicine and Therapeutics
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Targeted Cancer Therapies
There are several types of targeted therapies against...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
